These previous findings, coupled with our demonstration that MHC-II-expressing cancer cells can be efficiently recognized by TR-CD4, which in turn augments anti-tumor CD8+ T-cell response, indicate that immunotherapy focusing on tumor-recognizing CD4+ T cells could be a promising strategy for effective eradication of tumors. Here, CD4 is linked to neoplasm.